Skip to content
value.today

Horizon Pharma, Inc.

🇺🇸 Northbrook, Illinois, USAPharmaceuticalsFounded 2010
Total raised
$103 M
2 rounds on record
Latest round
$66 M
Mar 2012
First round on record
Apr 2010
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Horizon Pharma, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2012$66 MNo. 2$50 to $250 million

Horizon Pharma, Inc.: Raise no. 2, Mar 2012

Investors in this round

32 investors had bought by the notice of Mar 19, 2012: 32 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Horizon Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$66 M of $66 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$3,124,200
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Robert P. De Vaere · Executive Officer
  • Timothy P. Walbert · Executive Officer, Director
  • Gino W. Santini · Director
  • Jean-Francois W. Formela · Director
  • Jeff C. Himawan · Director
  • Jeffrey W. Bird · Director
  • Louis C. Bock · Director
  • Michael W. Grey · Director
  • Ronald W. Pauli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Stifel, Nicolaus & Company Incorporated (CRD 793) · broker-dealer Stifel, Nicolaus & Company Incorporated (CRD 793) · San Francisco, CaliforniaSold in CA
  • JMP Securities, LLC (CRD 22208) · broker-dealer JMP Securities, LLC (CRD 22208) · San Francisco, CaliforniaSold in CA
  • Cowen & Company LLC (CRD 7616) · broker-dealer Cowen & Company LLC (CRD 7616) · New York, New YorkSold in PA

Remarks in the notice

  • On the amounts: “Includes amounts receivable by the Company upon the exercise of warrants (assuming no net-issue exercise).”

Signed by Robert J. De Vaere, Executive Vice President and CFO. Source: SEC Form D, newest notice filed Mar 19, 2012. Read the notice at the SEC.

equity, optionsSEC
Apr 2010$37 MNo. 1$10 to $50 million

Horizon Pharma, Inc.: Raise no. 1, Apr 2010

Investors in this round

37 investors had bought by the notice of May 4, 2011: 37 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 9 investors are named for Horizon Pharma, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$37 M of $38 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Robert P. De Vaere · Executive Officer
  • Timothy P. Walbert · Executive Officer, Director
  • Hubert W. Birner · Director
  • Jean-Francois W. Formela · Director
  • Jeff C. Himawan · Director
  • Jeffrey W. Bird · Director
  • Louis C. Bock · Director
  • Peter W. Johann · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Robert J. De Vaere, Executive VP, CFO. Source: SEC Form D and 2 amendments, newest notice filed May 4, 2011. Read the notice at the SEC.

equity, debtSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Horizon Pharma, Inc. chose not to state its revenue in its newest notice of a funding round (Mar 2012).

    SEC Form D · Mar 2012

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Mar 2012

That is all the official record says: Horizon Pharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

9 named in official filings. Open an investor to see everything it has backed.

Investors in Horizon Pharma, Inc.
InvestorKindAmountRoundRoleSource
Atlas Venture Associates VI, L.P.Venture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Atlas Venture Entrepreneurs Fund VI LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Atlas Venture Fund VI GmbH & Co KGVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Atlas Venture Fund VI LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Essex Woodlands Health Ventures Fund VII LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner, director (Form 3, 2011)SEC Form 3
NGN Biomed Opportunity I Gmbh & Co. Beteiligungs KGCompanynot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
NGN BioMed Opportunity I L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Scale Venture Management II, LLCVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3
Scale Venture Partners II, LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2011)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 37 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Horizon Pharma, Inc.
NameRoleNamed in
Robert P. De VaereExecutive officerMar 2012
Timothy P. WalbertExecutive officerMar 2012
Gino W. SantiniDirectorMar 2012
Jean-Francois W. FormelaDirectorMar 2012
Jeff C. HimawanDirectorMar 2012
Jeffrey W. BirdDirectorMar 2012
Louis C. BockDirectorMar 2012
Michael W. GreyDirectorMar 2012
Ronald W. PauliDirectorMar 2012
Timothy P. WalbertDirectorMar 2012
Hubert W. BirnerDirectorMay 2011
Peter W. JohannDirectorMay 2011